We are live on
!
Find out more
PHS
PFM Health Sciences Portfolio holdings
AUM
$1.17B
1-Year Est. Return
92.19%
This Fund
S&P 500
This Quarter
Est. Return
+32.65%
1 Year Est. Return
+92.19%
3 Year Est. Return
+240.57%
5 Year Est. Return
+377.11%
10 Year Est. Return
+3,179.38%
AUM
$2.1B
AUM Growth
-$1.29B
(-38%)
Cap. Flow
-$1.85B
Cap. Flow
% of AUM
-88.17%
Top 10 Holdings %
Top 10 Hldgs %
43.41%
Holding
94
New
23
Increased
6
Reduced
30
Closed
33
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Biogen
BIIB
|
+$63.4M |
| 2 |
Elevance Health
ELV
|
+$54.6M |
| 3 |
Centene
CNC
|
+$44.4M |
| 4 |
Pfizer
PFE
|
+$34.7M |
| 5 |
ICU Medical
ICUI
|
+$28.5M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
BioMarin Pharmaceuticals
BMRN
|
+$121M |
| 2 |
Penumbra
PEN
|
+$97.1M |
| 3 |
Zimmer Biomet
ZBH
|
+$77.5M |
| 4 |
NXP Semiconductors
NXPI
|
+$75.2M |
| 5 |
Microchip Technology
MCHP
|
+$72.3M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 76.11% |
| 2 | Miscellaneous | 20.48% |
| 3 | Technology | 2.78% |
| 4 | Consumer Discretionary | 0.53% |
| 5 | Financials | 0.1% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1
CALL
Gilead Sciences
GILD
$187B
| $197M | 9.36% |
+3,024,200
| New | +$197M |
|
|
ALXN
2
DELISTED
Alexion Pharmaceuticals
ALXN
| $116M | 5.55% |
1,076,442
-370,170
| -26% | -$39.6M |
|
3
CALL
Cigna
CI
$74.7B
| $106M | 5.06% |
+519,500
| New | +$95.2M |
|
|
4
Gilead Sciences
GILD
$187B
| $87.8M | 4.18% |
1,351,736
-492,124
| -27% | -$32M |
|
|
BOLD
5
DELISTED
Audentes Therapeutics, Inc
BOLD
| $73.8M | 3.51% |
1,232,873
-1,083,065
| -47% | -$40.6M |
|
|
6
Penumbra
PEN
$12.7B
| $68.8M | 3.28% |
418,792
-610,772
| -59% | -$97.1M |
|
|
NVRO
7
DELISTED
NEVRO CORP.
NVRO
| $67.8M | 3.23% |
577,163
+180,893
| +46% | +$17.9M |
|
|
8
Biogen
BIIB
$32.6B
| $67.8M | 3.23% |
+228,328
| New | +$63.4M |
|
|
9
Zimmer Biomet
ZBH
$18.7B
| $66.3M | 3.16% |
455,906
-561,571
| -55% | -$77.5M |
|
|
10
Elevance Health
ELV
$88.4B
| $60M | 2.86% |
+198,548
| New | +$54.6M |
|
|
AERI
11
DELISTED
Aerie Pharmaceuticals
AERI
| $58.3M | 2.78% |
2,413,464
+582,540
| +32% | +$12.1M |
|
|
12
Cigna
CI
$74.7B
| $54.3M | 2.59% |
265,717
-131,967
| -33% | -$24.2M |
|
|
AGN
13
DELISTED
Allergan plc
AGN
| $53.8M | 2.56% |
281,548
-174,050
| -38% | -$31.4M |
|
14
IQVIA
IQV
$44.1B
| $53.1M | 2.53% |
343,567
-133,435
| -28% | -$19.5M |
|
|
15
Centene
CNC
$33.1B
| $51.5M | 2.45% |
+819,229
| New | +$44.4M |
|
|
ARNA
16
DELISTED
Arena Pharmaceuticals Inc
ARNA
| $48.6M | 2.32% |
1,070,616
-1,200,920
| -53% | -$56.8M |
|
|
17
BioMarin Pharmaceuticals
BMRN
$12.9B
| $46.8M | 2.23% |
553,634
-1,595,417
| -74% | -$121M |
|
|
KRTX
18
DELISTED
Karuna Therapeutics, Inc. Common Stock
KRTX
| $45.4M | 2.16% |
602,551
+191,908
| +47% | +$8.41M |
|
19
HCA Healthcare
HCA
$87.7B
| $41.3M | 1.97% |
279,411
-137,322
| -33% | -$18.4M |
|
20
Novartis
NVS
$304B
| $40.7M | 1.94% |
442,640
-246,960
| -36% | -$22.2M |
|
|
21
Pfizer
PFE
$162B
| $36.2M | 1.72% |
+972,975
| New | +$34.7M |
|
|
DERM
22
DELISTED
Dermira, Inc.
DERM
| $34.4M | 1.64% |
2,271,180
-1,558,356
| -41% | -$13.5M |
|
23
Icon
ICLR
$12.7B
| $33.3M | 1.59% |
193,577
-43,598
| -18% | -$6.72M |
|
|
IMMU
24
DELISTED
Immunomedics Inc
IMMU
| $31.7M | 1.51% |
+1,499,239
| New | +$26.4M |
|
25
iRhythm Holdings
IRTC
$4.06B
| $31.2M | 1.49% |
458,241
-622,818
| -58% | -$42.3M |
|
Similar funds
JC
PRS
MK
HCP
EC
M
CCM
VFP
PFM Health Sciences's Q4 2019 Portfolio in Review
As of Q4 2019, PFM Health Sciences held 94 positions worth $2.1B, down 38% from $3.39B the previous quarter. Its ten largest holdings account for 43% of the portfolio.
PFM Health Sciences withdrew a net $1.85B in Q4 2019, closing 33 positions and reducing 30 holdings. Its most notable exit was Wellcare Health Plans, Inc., an estimated $68.3M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 76% of assets, up from 64% a quarter earlier, followed by Miscellaneous and Technology.
Against the trend, PFM Health Sciences opened a new position in Biogen worth $67.8M.
- PFM Health Sciences's largest Q4 2019 buy was Biogen: 228,328 shares worth $67.8M.
- PFM Health Sciences added most to NEVRO CORP. in Q4 2019, an estimated $17.9M increase.
- PFM Health Sciences's biggest Q4 2019 reduction was BioMarin Pharmaceuticals, cutting an estimated $121M.
- PFM Health Sciences fully exited Wellcare Health Plans, Inc. in Q4 2019, selling an estimated $68.3M.
- PFM Health Sciences's ten largest holdings make up 43% of its $2.1B portfolio in Q4 2019.
- PFM Health Sciences opened 23 new positions and closed 33 in Q4 2019.
- PFM Health Sciences's portfolio value fell 38% quarter-over-quarter to $2.1B.
Based on PFM Health Sciences's 13F filing for Q4 2019, filed 14 Feb 2020.